Develops cell therapies for autoimmune diseases and cancers.
Dec 2025Revenue $0.00/yrExpenses $89.8M/yr
No trendCash runway ≈ 4.5 years from Jun 2026
Figures by year
When will Artiva Biotherapeutics be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Dec 2025, revenue was $0.00 and expenses $89.8M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $0.00 | $89.8M | −$89.8M |
| Dec 2024 | $251K | $67.5M | −$67.3M |
| Dec 2023 | $33.5M | $64.2M | −$30.7M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.